Squarepoint Ops LLC Purchases New Shares in Masimo Co. (NASDAQ:MASI)

Squarepoint Ops LLC acquired a new position in Masimo Co. (NASDAQ:MASI) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 9,686 shares of the medical equipment provider’s stock, valued at approximately $1,220,000.

A number of other institutional investors and hedge funds have also modified their holdings of MASI. Parallel Advisors LLC grew its holdings in shares of Masimo by 48.3% during the 4th quarter. Parallel Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $52,000 after acquiring an additional 145 shares in the last quarter. Lighthouse Investment Partners LLC acquired a new position in Masimo in the 4th quarter valued at $4,371,000. 13D Management LLC lifted its position in shares of Masimo by 99.4% during the 4th quarter. 13D Management LLC now owns 44,095 shares of the medical equipment provider’s stock worth $5,168,000 after purchasing an additional 21,982 shares during the last quarter. Neuberger Berman Group LLC bought a new position in Masimo in the 4th quarter worth approximately $505,000. Finally, Brown Capital Management LLC increased its position in Masimo by 21.9% during the fourth quarter. Brown Capital Management LLC now owns 26,972 shares of the medical equipment provider’s stock worth $3,161,000 after acquiring an additional 4,849 shares during the period. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Trading Up 4.8 %

MASI stock opened at $138.83 on Friday. The business’s 50 day moving average is $119.78 and its 200-day moving average is $125.02. Masimo Co. has a 1-year low of $75.22 and a 1-year high of $153.93. The firm has a market cap of $7.38 billion, a P/E ratio of 94.44 and a beta of 0.99. The company has a current ratio of 2.09, a quick ratio of 1.15 and a debt-to-equity ratio of 0.55.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.09. Masimo had a net margin of 3.94% and a return on equity of 14.07%. The firm had revenue of $496.30 million for the quarter, compared to analyst estimates of $493.92 million. During the same period in the previous year, the business earned $0.62 earnings per share. The company’s revenue for the quarter was up 9.0% compared to the same quarter last year. Equities analysts anticipate that Masimo Co. will post 3.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

MASI has been the topic of several research reports. Piper Sandler boosted their price objective on shares of Masimo from $160.00 to $165.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research report on Friday, September 20th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Masimo has a consensus rating of “Moderate Buy” and a consensus price target of $144.67.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.